The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence.
 
Hope S. Rugo
Consulting or Advisory Role - Celltrion; Ionis Pharmaceuticals
Research Funding - Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Daiichi Sankyo; Macrogenics; Merck; Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology
 
Louis W. C. Chow
Consulting or Advisory Role - OBI Pharma
 
Javier Cortes
Stock and Other Ownership Interests - MedSIR
Honoraria - Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; Biothera; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; ERYTECH Pharma; GlaxoSmithKline; Leuko; Lilly; Merck Sharp & Dohme; Merus; Polyphor; Roche; Seagen; SERVIER
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Eisai; Novartis; Pfizer; Roche
 
Peter A. Fasching
Honoraria - Amgen; AstraZeneca; BioNTech (Inst); Celgene; Cepheid (Inst); Daiichi Sankyo; Eisai; Hexal; Lilly; Merck Sharp & Dohme; Myelo Therapeutics GmbH; Novartis; Pfizer; Puma Biotechnology; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Hexal; Macrogenics; Merck Sharp & Dohme; Myelo Therapeutics GmbH; Novartis; Pfizer; Puma Biotechnology; Roche; Teva
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst)
 
Pei Hsu
Employment - OBI Pharma
 
Chiun-Sheng Huang
No Relationships to Disclose
 
Sung-Bae Kim
Honoraria - DAEHWA Pharmaceutical; Enzychem Lifesciences; ISU ABXIS
Consulting or Advisory Role - AstraZeneca; DAEHWA Pharmaceutical; Enzychem Lifesciences (Inst); ISU Abxis; Lilly (Inst)
Research Funding - Dongkook Pharma (Inst); Genzyme (Inst); Kyowha Kirin (Inst); Novartis (Inst)
 
Yen-Shen Lu
Honoraria - Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Research Funding - Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Eisai; Novartis; Pfizer; Roche
 
Michelle E. Melisko
Stock and Other Ownership Interests - Merrimack (I)
Honoraria - Agendia; Genentech (I); Pfizer (I)
Speakers' Bureau - Agendia; Genentech (I); Pfizer (I)
Research Funding - Celldex (Inst); Genentech (Inst); Lilly (Inst); Nektar (Inst); Novartis (Inst); Puma Biotechnology (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Multiple patents related to immunoliposomal drugs being studied and potentially brought to market by Merrimack (I)
 
Rita Nanda
Consulting or Advisory Role - Aduro Biotech; Athenex; Daiichi Sankyo; Genentech/Roche; ION Pharma; Macrogenics; Merck; Pfizer; Seagen
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Other Relationship - G1 Therapeutics
 
Priyanka Sharma
Consulting or Advisory Role - AstraZeneca; Epic Sciences; Exact Sciences; Merck; Myriad Genetics; Novartis; Pfizer; Puma Biotechnology; Seagen
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Cosmo Biosciences (I); Merck (Inst); Novartis (Inst)
 
Richard B. Schwab
Leadership - Procend, Inc.
Stock and Other Ownership Interests - Samumed (I)
Patents, Royalties, Other Intellectual Property - The patent covers sialylated glycans and antibodies that specifically bind to them for early detection and diagnosis of cancer. (Inst)
Expert Testimony - Puma Biotechnology
 
Binghe Xu
Speakers' Bureau - AstraZeneca; Eisai; Pfizer; Roche
Research Funding - Jiangsu Hengrui Medicine (Inst)